miR-873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1

HUI GONG1,2*, LISHAN FANG3*, YIFAN LI1, JIHUI DU1, BEI ZHOU1, XIU WANG3, HEKAI ZHOU1, LINGLI GAO1, KAIXIN WANG4 and JUAN ZHANG4

1Central Laboratory, 2Shenzhen Key Laboratory of Endogenous Infection, 3Clinical Laboratory and 4Department of Pathology, Shenzhen Nanshan People’s Hospital/Affiliated Shenzhen Sixth Hospital of Guangdong Medical University; 5Central Laboratory, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong 518033, P.R. China

Received June 20, 2017; Accepted December 20, 2017

DOI: 10.3892/or.2018.6199

Abstract. MicroRNA-873 (miR-873) has been reported to be dysregulated in a variety of malignancies, however, the biological function and underlying molecular mechanism of miR-873 in colorectal cancer (CRC) remain unclear. In the present study we found that the expression levels of miR-873 were markedly decreased in CRC cell lines and tissues from patients. Statistical analysis revealed that miR-873 expression was inversely correlated with the disease stage of CRC. Kaplan-Meier survival analysis revealed that patients with CRC with lower miR-873 expression had shorter overall survival rates. Additionally, downregulation of miR-873 enhanced the proliferation of CRC cells, while upregulation of miR-873 reduced this proliferation. Furthermore, we found that tumor necrosis factor (TNF) receptor-associated factor 5 (TRAF5) and transforming growth factor-β (TGF-β) signaling has been demonstrated to play vital roles in the development and progression of a large array of malignancies, including CRC (9,10). Stimulatory factors, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), or pathogen-derived components that include bacterial lipopolysaccharides (LPS), bind to their respective receptors, leading to the rapid recruitment of tumor necrosis factor receptor type 1-associated DEATH domain (TRADD), cellular inhibitor of apoptosis protein 1 (cIAP1), baculoviral IAP repeat-containing protein 3 (cIAP2), and TNF receptor-associated factors (TRAFs), including TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6. As molecular activators for the NF-κB signaling pathway, TRAFs function as E3 ubiquitin ligases that induce the K63 polyubiquitination of receptor-interacting protein 1 (RIP1), resulting in activation of the transforming growth factor-activated kinase-1 (TAK1)/TAB2/TGF-β-activated kinase 1 (MAP3K7) binding protein 1 (TAB1) complex. During this process, TAB1, TAB2, and TAB3 form a complex with TAK1, which phosphorylates and activates the inhibitor of apoptosis protein 1 (cIAP1), baculoviral IAP repeat-containing protein 3 (cIAP2), and TNF receptor-associated factors (TRAFs), including TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6. As molecular activators for the NF-κB signaling pathway, TRAFs function as E3 ubiquitin ligases that induce the K63 polyubiquitination of receptor-interacting protein 1 (RIP1), resulting in activation of the transforming growth factor-activated kinase-1 (TAK1)/TAB2/TGF-β-activated kinase 1 (MAP3K7) binding protein 1 (TAB1) complex. During this process, TAB1, TAB2, and TAB3 form a complex with TAK1, which phosphorylates and activates the inhibitor of the NF-κB kinase (IKK)-α/β/γ kinase complex, leading to nuclear translocation and activation of NF-κB (11-13). Thus, further investigations into the mechanism of regulation of the NF-κB pathway key components, such as TRAF2, TRAF5, TAK1, TAB1, and TAB3, would increase our knowledge of the mechanisms underpinning the constitutive activation of NF-κB in cancer.
MicroRNAs (miRNAs), a class of small non-coding RNAs, function as negative regulators of gene expression by interacting with the 3'-untranslated region (3'-UTR) of their target mRNAs (14). These miRNAs, which are approximately 20-25 nucleotides in length, play important roles in a variety of physiological and pathological processes, such as development, cell proliferation, differentiation, and senescence (15). Previous research has revealed that miRNAs are involved in carcinogenesis via regulation of several key cellular processes, including cell proliferation, apoptosis, migration, invasion, and angiogenesis (16). Numerous miRNAs have been reported to be upregulated or downregulated in various types of cancer, demonstrating their potential roles as oncogenes or tumor suppressors (17-20). The altered expression of miRNAs in cancers suggests that they may serve as potential diagnostic or prognostic biomarkers for cancer (21-23). For instance, in glioma, ovarian cancer, and breast cancer, miR-873 is downregulated and may act as tumor suppressor (24-28). However, miR-873 has been revealed to be upregulated in lung adenocarcinoma, where it promotes tumor cell proliferation and migration (29).

In the present study we revealed that miR-873 was downregulated in CRC and this was correlated with a poor prognosis for patients with CRC. Furthermore, we determined that downregulation of miR-873 enhanced CRC cell proliferation by directly targeting TRAF5 and TAB1, leading to activation of NF-κB signaling. These results demonstrated that miR-873 served as a tumor-suppressive miRNA in the development and progression of CRC.

Materials and methods

Cells. The CRC cell lines (SW620, SW480, DLD1, HCT116, LoVo, and HT-29) were purchased from the American Type Culture Collection (Manassas, VA, USA). The normal human colon mucosal epithelial cell line (NCM460) and the CRC cell line (KM12) were purchased from the BeNa Culture Collection (Beijing, China). The normal human colon mucosal epithelial cell line (NCM460) and seven CRC cell lines (SW620, SW480, DLD1, HCT116, KM12, LoVo, and HT-29) were grown in Dulbecco's modified Eagle's medium (Invitrogen; Thermo Fisher Scientific, Foster City, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific) and 100 units of penicillin-streptomycin.

Patient information and tissue specimens. This study was conducted on a total of 125 paraffin-embedded and archived CRC samples, which were diagnosed histopathologically at the Affiliated Shenzhen Sixth Hospital of Guangdong Medical University from 2003 to 2012. Informed patient consent and approval from the Institutional Research Ethics Committee of the Affiliated Shenzhen Sixth Hospital of Guangdong Medical University was obtained for use of these clinical materials for research purposes. Clinical information regarding the samples is summarized in Table I. Ten CRC tissue samples and their matched adjacent non-cancerous colorectal tissues were frozen and stored in liquid nitrogen until further use.

Plasmids and transfection. The 3'-UTR regions of human TRAF5 (from 1801 to 2211 nt, containing a predicted conserved miR-873 binding site) and TAB1 (from 3288 to 3700 nt, containing a predicted conserved miR-873 binding site) were generated by PCR and cloned into the modified pGL3-control luciferase reporter plasmid (Promega Corporation, Madison, WI, USA). Primer sequences were as follows: TRAF5-3'UTR sense, 5'-ACTCCGCGGATCCCAAGATTTAATTTTTCTAAGGATCAC-3'; TRAF5-3'UTR antisense, 5'-CTAATGCTGGTGTTTGTTCGAGAT-3'; TAB1-3'UTR sense, 5'-ACTCCGCGGAGGGACGTC TGGCCCTCAGTTTGC-3' and antisense, 5'-CTAATGCTGGTGTTTGTTCGAGAT-3'; TAB1-3'UTR constructs were created using a Stratagene QuickChange Mutagenesis kit (Stratagene; Agilent Technologies Inc., La Jolla, CA, USA). A miR-873 mimic, miR-873 inhibitor, and the negative control (NC) were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). The sequences were as follows: miR-873 mimic, 5' GCAGGAAC uuGuGAGuCu CCA-3'; miR-873-NC sense, 5' UUUUGACACAAACAGG UACUG-3'; miR-873 inhibitor, 5'-AGGAACACAAAGU UCCUG-3'. The miR-873 mimic or miR-873 inhibitor (the miR-873 inhibitor is a locked nucleic acid (LNA)/O-Methyl oligo (OMe) modified antisense oligonucleotide designed specifically to bind to and inhibit the endogenous miR-873 molecule) was transfected into cells using the Lipofectamine 2000 reagent (Invitrogen; Thermo Fisher Scientific) according to the manufacturer's instructions.

RNA extraction, reverse transcription (RT), and quantitative PCR (qPCR). Total RNA from the indicated tissues or cells was extracted using the TRIzol reagent (Life Technologies; Thermo Fisher Scientific, Carlsbad, CA, USA), according to the manufacturer's instructions. Complementary DNA (cDNA) was amplified and quantified on an ABI PRISM 7500 Sequence Detection system (Applied Biosystems; Thermo Fisher Scientific, Foster City, CA, USA) using SYBR Green I (Roche Diagnostics, Grenzach-Wyhlen, Germany). miRNA quantification was determined using Bulge-loop™ miRNA quantitative reverse transcription PCR (qRT-PCR) Primer Set (one RT primer and a pair of qPCR primers for each set) specific for U6 and miR-873 that were designed and synthesized by Guangzhou RiboBio Co., Ltd. The catalog numbers of these primers were as follows: miR-873 RT primer (ssD809230648), miR-873 forward primer (ssD090525061), miR-873 reverse primer (ssD089261711), U6 RT primer (ssD0904071008), U6 forward primer (ssD0904071006), and U6 reverse primer (ss D0904071007). The quantitative PCR (qPCR) conditions were as follows: incubation at 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec, and 60°C for 1 min. The expression of miR-873 was defined based on the quantification cycle (Cq), and the relative fold changes between normal human colon mucosal epithelial cell line and the CRC cell lines, and between CRC tissues and their tumor-adjacent tissues (TATs), were calculated according to the formula 2^[-(Cq of miR-873) - (Cq of U6)] after normalization to the expression of U6 small nuclear RNA as a reference (30). REST-MCS beta software version 2 was used to further analyze the qPCR data.

MTT assays. Cells (2x10^4/well) were seeded into 96-well plates. Transfection was performed 12 h later. At the indicated time-points, 100 μl of sterile 3-(4,5-Dimethyl-2-thiazolyl)-2,5-
5-diphenyl-2H-tetrazoliumbromide (MTT) dye (0.5 mg/ml; Sigma-Aldrich, St. Louis, MI, USA) was added and incubated for 4 h at 37˚C. The culture medium was subsequently removed, and 150 µl of dimethyl sulfoxide (DMSO; Sigma-Aldrich) was added. The absorbance was assessed at a wavelength of 490 nm. All experiments were performed in triplicate.

**Colony formation assay.** Cells (8x10^2/well) were seeded into 6-well plates and cultured for 10 days. The colonies were stained with 1% crystal violet for 30 sec after incubation with 10% formaldehyde for 5 min. Colonies were counted only if they contained more than 50 cells, according to the established criteria for colony formation (31-33).

**Western blot analysis.** Cell lysates were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Billerica, MA, USA). The membranes were probed with antibodies against TRAF5 (anti-TRAF5 antibody; 1:1,000; mouse, polyclonal; cat. no. SAB1409766) and TAB1 (anti-TAB1 antibody; 1:500; rabbit, polyclonal; cat. no. SAB4301002; both from Sigma-Aldrich) overnight at 4˚C, followed by incubation with horseradish peroxidase-conjugated secondary antibodies (1:2,000; goat; cat. no. 7074 and 1:2,000; horse; cat. no. 7076; Cell Signaling Technology, Danvers, MA, USA) for 1 h at 20˚C. The membranes were stripped and re-probed with an anti-α-tubulin antibody (Sigma-Aldrich) as a loading control.

**Luciferase assay.** Cells (2x10^4/well) were seeded in triplicate in 48-well plates and allowed to settle for 24 h. Next, 100 ng of the luciferase reporter plasmids or the control plasmid, both with 1 ng of pRL-TK Renilla plasmid (Promega Corporation), were transfected into cells using the Lipofectamine 2000 reagent (Invitrogen; Thermo Fisher Scientific), according to the manufacturer’s recommendation. Luciferase and Renilla signals were assessed 24 h after transfection using a Dual Luciferase Reporter assay kit (Promega Corporation), according to the manufacturer’s instructions.

**Immunohistochemistry (IHC) and hematoxylin and eosin (H&E) staining.** Histology was performed to quantify Ki67 expression in 10 paraffin-embedded human CRC samples. IHC was performed on sections using an anti-Ki67 antibody (1:1; mouse, monoclonal; cat. no. IR62661-2; Dako; Agilent Technologies, Inc., Glostrup, Denmark). H&E staining was performed using Mayer's hematoxylin solution. Immunostaining of the sections was quantified and scored independently by two observers based on both the proportion of positively-stained tumor cells and the intensity of staining. The proportion of tumor cells enriched for Ki67 was scored as follows: 0 (no positive tumor cells), 1 (<10% positive tumor cells), 2 (10-50% positive tumor cells), and 3 (>50% positive tumor cells). The intensity of staining was scored according to the following criteria: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellow brown), and 3 (strong staining, brown). The staining index (SI) was calculated as the proportion of positive tumor cells x the staining intensity score. Using this scoring method, we evaluated the expression of Ki67 by determining the SI, which was scored as 0, 1, 2, 3, 4, 6 and 9.

**Statistical analysis.** All values are presented as the means ± standard deviation (SD). Student's t-test was used to determine the statistical differences. The Chi-square test was used to analyze the relationship between miR-873 expression and clinicopathological characteristics. Multivariate statistical analysis was performed using a Cox regression model. Survival curves

### Table I. Clinicopathological characteristics of studied patients and expression of mir-873 in CRC.

| Factors                  | No. (%) | ( % ) |
|--------------------------|---------|-------|
| Sex                      |         |       |
| Male                     | 68      | 54.4  |
| Female                   | 57      | 45.6  |
| Age (years)              |         |       |
| ≤62                      | 64      | 51.2  |
| >62                      | 61      | 48.8  |
| Tumor site               |         |       |
| Colon                    | 61      | 48.8  |
| Rectal                   | 64      | 51.2  |
| Dukes’ stage             |         |       |
| A                        | 17      | 13.6  |
| B                        | 36      | 28.8  |
| C                        | 45      | 36.0  |
| D                        | 27      | 21.6  |
| Clinical stage           |         |       |
| I                        | 17      | 13.6  |
| II                       | 37      | 29.6  |
| III                      | 44      | 35.2  |
| IV                       | 27      | 21.6  |
| T classification         |         |       |
| T1                       | 2       | 1.6   |
| T2                       | 30      | 24.0  |
| T3                       | 42      | 33.6  |
| T4                       | 51      | 40.8  |
| N classification         |         |       |
| N0                       | 63      | 50.4  |
| N1                       | 39      | 31.2  |
| N2                       | 23      | 18.4  |
| M classification         |         |       |
| M0                       | 97      | 77.6  |
| M1                       | 28      | 22.4  |
| Histological differentiation |      |       |
| Well                     | 29      | 23.2  |
| Moderate                 | 65      | 52.0  |
| Poor                     | 31      | 24.8  |
| Vital status             |         |       |
| Alive                    | 49      | 39.2  |
| Dead                     | 76      | 60.8  |
| Expression of mir-873    |         |       |
| Low                      | 62      | 49.6  |
| High                     | 63      | 50.4  |

CRC, colorectal cancer; T, tumor; N, node; M, metastasis.
were plotted using the Kaplan-Meier method and compared using the log-rank test. Statistical analyses were performed using the SPSS 19.0 software (SPSS, Chicago, IL, USA). P≤0.05 was considered to indicate a statistically significant result.

Results

miR-873 is downregulated in CRC cell lines and CRC tissues. To examine the expression levels of miR-873 expression in CRC, we conducted qPCR in one normal human colon mucosal epithelial cell line, seven CRC cell lines, and ten pairs of CRC samples (T) and TATs. The results revealed that miR-873 was markedly decreased in all seven CRC cell lines (SW620, SW480, DLD1, HCT116, KM12, LoVo, and HT-29) compared with the normal human colon mucosal epithelial cell line NCM460 (Fig. 1A). Consistent with the results obtained from the cell lines, miR-873 expression in the ten CRC tissue samples was significantly lower compared with that in their TATs (Fig. 1B), indicating that the expression of miR-873 was downregulated in CRC.
miR-873 inhibits the proliferation of CRC cells. To investigate the biological significance of miR-873 downregulation during the progression of CRC, we transfected the miR-873 mimic into HCT116 and SW480 cell lines. MTT and colony formation assays revealed that overexpression of miR-873 markedly decreased the growth rates of both CRC lines compared with the negative control (NC) (Fig. 2A-C). Furthermore, transfection of the miR-873 inhibitor significantly increased the growth rates of both CRC lines compared with that of the NC (Fig. 2D-F). However, neither transfection of miR-873 nor the miR-873 inhibitor altered the apoptotic rates of CRC cells (data not shown). Therefore, these results revealed that miR-873 suppressed the proliferation of CRC cells.

TRAF5 and TAB1 are direct targets of miR-873 in CRC cells. To identify the direct targets of miR-873 regulation, we searched publicly available databases (TargetScan, Pictar, and miRanda) and found that TRAF5 and TAB1, which encode components of the NF-κB pathway, may be potential targets (Fig. 3A). As predicted, western blot analysis revealed that TRAF5 and TAB1 reporter activity in the indicated cells. Error bars represent the mean ± SD from three independent experiments. *P<0.05. TRAF5, tumor necrosis receptor-associated factor 5; TAB1, TGF-β activated kinase 1 (MAP3K7) binding protein 1; NF-κB, nuclear factor κB.

Figure 3. miR-873 directly targets TRAF5 and TAB1 to inhibit NF-κB signaling. (A) Predicted binding sites of miR-873 to the 3'-UTRs of TRAF5 and TAB1. (B-D) Western blotting and quantification of TRAF5 and TAB1 in the indicated cells. α-tubulin was used as a loading control. The relative expression of the proteins was quantified by Image-Pro 6.0 software. (E) Luciferase assays on HCT116 and SW480 cells transfected with the pGL3 control reporter, pGL3-target-3'-UTR reporter, or pGL3-target-3'-UTR-mut reporter with miR-873 mimic or miR-873 inhibitor oligonucleotides. (F) NF-κB luciferase reporter activity in the indicated cells. Error bars represent the mean ± SD from three independent experiments. *P<0.05. TRAF5, tumor necrosis receptor-associated factor 5; TAB1, TGF-β activated kinase 1 (MAP3K7) binding protein 1; NF-κB, nuclear factor κB.
ectopic expression of miR-873 in HCT116 and SW480 cells decreased the levels of the TRAF5 and TAB1 proteins, whereas ectopic expression of the miR-873 inhibitor increased their levels (Fig. 3B-D). However, we determined that the mRNA expression levels of TRAF5 and TAB1 did not exhibit evident alterations in the miR-873 dysregulated cells (data not shown), suggesting that miR-873 negatively regulated the expression of these proteins at the translation level. To further test this, we subcloned the 3’-UTRs of TRAF5 and TAB1 into the pGL3 luciferase reporter. Transfection of miR-873 consistently attenuated the luciferase activity of the TRAF5-3’-UTR and TAB1-3’-UTR luciferase reporter in both HCT116 and SW480 cells, whereas transfection of the miR-873 inhibitor rescued luciferase suppression. However, dysregulation of miR-873 did not result in the alteration of the reporter activities driven by the 3’-UTRs of TRAF5 and TAB1 mutated within the miR-873-binding seed regions (Fig. 3E). Collectively, these results further supported the view that TRAF5 and TAB1 are genuine targets of miR-873.

Furthermore, the luciferase assay revealed that ectopic expression of miR-873 in HCT116 and SW480 cells significantly reduced NF-κB luciferase activity, while ectopic expression of the miR-873 inhibitor enhanced NF-κB luciferase activity (Fig. 3F). This suggested an important role for NF-κB signaling in the CRC cell proliferation induced by miR-873 downregulation.

miR-873 expression is correlated with clinical features and prognosis of patients with CRC. To further evaluate whether miR-873 downregulation was associated with the clinical features or prognosis of CRC, we examined the expression of miR-873 in a large cohort of clinical CRC samples using qPCR and performed a correlation analysis between the clinicopathological features and the expression of miR-873. The data revealed that miR-873 expression was inversely correlated with Dukes’ stage (P=0.005), clinical stage (P=0.002), tumor-node-metastasis (TNM) classification (T, P=0.036; N, P=0.001; M, P=0.010), and histological differentiation (P=0.014) (Table II). Additionally, Kaplan-Meier survival analysis revealed that patients with CRC with lower miR-873 expression levels had shorter overall survival (Fig. 4). Moreover, univariate and multivariate analysis indicated that miR-873 expression levels were an independent prognostic factor for CRC (Table III). Collectively, these results indicated a possible link between miR-873 downregulation and CRC progression.

Clinical relevance of miR-873 downregulation and cell proliferation in CRC. Finally, we examined whether the reduction in miR-873 expression induced cell proliferation in CRC

---

**Table II. Correlation between clinicopathological features of CRC patients and expression of mir-873.**

| Patient characteristics | Low or none (%) | High (%) | P-value |
|-------------------------|-----------------|----------|---------|
| Sex                     |                 |          |         |
| Male                    | 31 (24.8)       | 37 (29.6) | 0.372   |
| Female                  | 31 (24.8)       | 26 (20.8) |          |
| Age (years)             |                 |          |         |
| ≤62                     | 31 (24.8)       | 33 (26.4) | 0.859   |
| >62                     | 31 (24.8)       | 30 (24.0) |          |
| Dukes’ stage            |                 |          |         |
| A                       | 6 (4.8)         | 11 (8.8)  | 0.005   |
| B                       | 11 (8.8)        | 25 (20.0) |          |
| C                       | 26 (20.8)       | 19 (15.2) |          |
| D                       | 19 (15.2)       | 8 (6.4)   |          |
| Clinical stage          |                 |          |         |
| I                       | 6 (4.80)        | 11 (8.80) | 0.002   |
| II                      | 11 (8.80)       | 26 (20.8) |          |
| III                     | 25 (20.0)       | 19 (15.2) |          |
| IV                      | 20 (16.0)       | 7 (5.6)   |          |
| T classification        |                 |          |         |
| T1                      | 0 (0.0)         | 2 (1.6)   | 0.036   |
| T2                      | 16 (12.8)       | 14 (11.2) |          |
| T3                      | 15 (12.0)       | 27 (21.6) |          |
| T4                      | 31 (24.8)       | 20 (16.0) |          |
| N classification        |                 |          |         |
| N0                      | 23 (18.4)       | 40 (32.0) | 0.001   |
| N1                      | 20 (16.0)       | 19 (15.2) |          |
| N2                      | 19 (15.2)       | 4 (3.2)   |          |
| M classification        |                 |          |         |
| M0                      | 42 (33.6)       | 55 (44.0) | 0.010   |
| M1                      | 20 (16.0)       | 8 (6.4)   |          |
| Histological differentiation |             |          |         |
| Well                    | 21 (16.8)       | 8 (6.4)   | 0.014   |
| Moderate                | 26 (20.8)       | 39 (31.2) |          |
| Poor                    | 15 (12.0)       | 16 (12.8) |          |
| Vital status            |                 |          |         |
| Alive                   | 15 (12.0)       | 34 (27.2) | 0.001   |
| Dead                    | 47 (37.6)       | 29 (23.2) |          |

CRC, colorectal cancer; T, tumor; N, node; M, metastasis.
samples and whether this was clinically relevant. IHC analysis of ten CRC specimens revealed that low miR-873-expressed specimens had a higher proportion of cells expressing the proliferation marker Ki67. In contrast, high miR-873-expressed specimens displayed a small proportion of Ki67-positive cells among the ten CRC specimens (Fig. 5A). Correlation analysis revealed that miR-873 expression levels were inversely correlated with Ki67 in these CRC samples (Fig. 5B). Collectively, these results established that miR-873 suppressed CRC cell proliferation via inhibition of TRAF5 and TAB1, which are key components of the NF-κB signaling pathway.

Discussion

The key finding of the current study is that miR-873 is a tumor-suppressive miRNA in CRC. Our data revealed that miR-873 was significantly downregulated in both CRC cell lines and primary CRC specimens. Furthermore, downregulation of miR-873 expression was associated with more advanced tumor stages and poor prognoses for patients with CRC. Ectopic expression of miR-873 inhibited CRC cell proliferation, whereas silencing of miR-873 promoted cell proliferation. In addition, we demonstrated that miR-873 suppressed the NF-κB pathway by directly targeting TRAF5 and TAB1, which encode vital components of this pathway. Collectively, our results demonstrated that miR-873 plays a critical role in the tumorigenesis and progression of CRC and may represent an important target for clinical intervention of CRC.

Previous research has revealed that miRNAs are involved in tumor initiation, progression, metastasis, and response to chemotherapy in CRC. In 2003, the first study describing the roles of miRNAs in CRC was published, which revealed...
that miR-143 and miR-145 were specifically dysregulated in CRC, and multiple other miRNAs were found to contribute to CRC by regulating critical target mRNAs (34). For example, several studies have revealed the dysregulation of a variety of tissue-specific miRNAs, e.g., miR-21, miR-181b, miR-155, miR-92a, and let-7, as well as some circulating miRNAs, e.g., miR-26a, miR-21, miR-126, and miR-203 in CRC (35,36). These miRNAs exert their effects by negatively regulating their targets, such as p53, c-Met, K-Ras, COX-2, Rb, and the Bcl-2 family (37). Accumulating evidence indicates that miRNAs may serve as targets for miRNA-based therapeutics of CRC. Inhibition of overexpressed oncogenic miRNAs or introduction of tumor-suppressive miRNAs into cancer cells may represent novel treatment strategies for CRC therapy in the future (38).

Previously, it was shown that miR-873 is dysregulated in a variety of malignancies. Notably, miR-873 was downregulated in glioblastoma, and inhibited tumorigenesis and metastasis by suppressing the expression of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) (24,25). In addition, miR-873 enhanced the sensitivity of glioma cells to cisplatin by targeting Bcl-2 (26). It was also reported that overexpression of miR-873 increased the sensitivity of ovarian cancer cells to cisplatin and paclitaxel by targeting multidrug resistance protein 1 (MDR1) (27). However, there are also studies which have reported that cisplatin is not a P-glycoprotein substrate and multidrug resistance induced by cisplatin in ovarian carcinoma cell lines was not due to overexpression of MDR1 and MDR3, both of which are P-glycoproteins (39,40). Therefore, the controversial mechanisms of multdrug resistance induced by cisplatin in ovarian carcinoma warrant further investigation. In addition, miR-873 was downregulated in tamoxifen-resistant breast cancer cell lines, while overexpression of miR-873 reversed tamoxifen resistance by targeting cyclin-dependent kinase 3 (CDK3) (28). By contrast, however, Gao et al reported that miR-873 may act as an oncogene in lung adenocarcinoma since it increased tumor cell proliferation and migration via direct inhibition of SRC1N1 expression (29). Collectively, these findings indicated that miR-873 can act as either a tumor-suppressive or -promoting miRNA depending on the type of cancer. In this context, we demonstrated that miR-873 inhibited CRC cell proliferation and functioned as a tumor-suppressive miRNA in CRC. Meanwhile, the inversely clinical relevance of miR-873 reduction with higher Ki67 signaling further supported the suppressive effect of miR-873 on proliferation in CRC. However, the inhibitory effect of miR-873 on proliferation in CRC warrants further investigation using an in vivo mouse model. In addition, the expression and biological function of miR-873 in other gastrointestinal tract cancers also warrant further clarification.

NF-κB is a family of transcription factors that controls the expression of a large number of genes related to inflammation, immune responses, development, survival, and proliferation (41). Since its discovery nearly three decades ago (42), numerous studies have reported that the NF-κB signaling pathway is frequently activated in a variety of human cancers and it is associated with tumor initiation and progression (6,8). The NF-κB signaling pathway plays critical roles in the physiological and pathological processes of CRC, and the relationship between CRC development and NF-κB signaling is becoming clear (43). Multiple research groups revealed that the constitutively activated form of NF-κB was frequently expressed in CRC cells (44-46). NF-κB may contribute to the progression of CRC by regulating the expression of diverse target genes that are involved in cell proliferation, angiogenesis, and metastasis (47). Therefore, the NF-κB pathway and its upstream and downstream network constitute a potential druggable target for therapeutic interventions (48). Although IKK complex-mediated NF-κB activation has been studied in great detail, the regulatory mechanism of the constitutive activation of NF-κB in CRC remains largely unknown. Herein, we found that miR-873 significantly inhibited the NF-κB pathway by directly targeting TRAF5 and TAB1, key components of the NF-κB pathway. Thus, our results indicated that miR-873 plays a regulatory role in NF-κB activation, and the effect of miR-873-induced activation of NF-κB on invasion, angiogenesis, or metastasis of CRC warrant further investigation.

In conclusion, the present study reported that miR-873 was downregulated in CRC and the expression level of miR-873 was correlated with CRC progression and prognosis. We have demonstrated, for the first time, that the upregulation of miR-873 markedly inhibited CRC cell proliferation by inhibiting the expression of two key components (TRAF5 and TAB1) of the NF-κB pathway. Therefore, our results demonstrated that miR-873 may play an important role in the progression of CRC and could represent a potential therapeutic target for CRC.

Acknowledgements

This study was supported by the Natural Science Foundation of China (nos. 81402310, 81672957 and 91529301) and the Science and Technology Innovation Committee of Shenzhen Municipality (nos. JCYJ20140411093600199 and JCYJ20160428180814307).

References

1. Haggart FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22: 191-197, 2009.
2. Weng W, Wei Q, Todon S, Yoshida K, Nagasaka T, Fujiwara T, Cai S, Qin H, Ma Y and Goel A: Circular RNA ciRS-7-a promising prognostic biomarker and a potential therapeutic target in colorectal cancer. Clin Cancer Res 23: 3918-3928, 2017.
3. Zeng J, Tang ZH, Liu S and Guo SS: Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol 23: 1780-1786, 2017.
4. Deng J, Lei W, Fu JC, Zhang L, Li JH and Xiong JP: Targeting miR21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun 443: 789-795, 2014.
5. Wieser M, Sauerland S, Arnold D, Schmied W and Reichercher-Schick A: Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials. BMC Cancer 10: 309-321, 2010.
6. Mohgimi-Dehkhordi B and Safaei A: An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol 4: 71-75, 2012.
7. Karin M and Greten FR: NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759, 2005.
8. Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell 132: 344-362, 2008.
9. Hoesel B and Schmid JA: The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 12: 86, 2013.
10. Wu D, Wu P, Zhao L, Huang L, Zhang Z, Zhao S and Huang J: NF-kB expression and outcomes in solid tumors: A systematic review and meta-analysis. Medicine (Baltimore) 94: e1687, 2015.

11. Chen X, Zeng X, Zhao F, Yang G and Wang J: MicroRNA-26b regulates cancer proliferation and cell cycle transition by suppressing TRAF5 in esophageal squamous cell carcinoma. Am J Transl Res 8: 1957-1970, 2016.

12. Jiang L, Yu L, Zhang X, Lei F, Wang L, Liu X, Wu S, Zhu J, Wu G, Cao L, et al: miR-92b silencing activates NF-kB and promotes aggressiveness in breast cancer. Cancer Res 76: 1101-1111, 2016.

13. Harhaj EW and Dixit VM: Deubiquitinases in the regulation of NF-κB signaling. Cell Res 21: 22-39, 2011.

14. Khella HW, Daniel N, Youssef L, Scorilas A, Nofech-Mozes R, Mirham L, Krylov SN, Liandeau E, Krizova A, Finelli A, et al: miR-10b is a prognostic marker in clear cell renal cell carcinoma. J Clin Pathol 70: 854-859, 2017.

15. Chen J, Wang M, Guo M, Xie Y and Cong YS: miR-127 regulates cell proliferation and senescence by targeting BCL6. PLoS One 8: e60266, 2013.

16. Li M, Wang Y, Song Y, Bu R, Yin B, Fei X, Guo Q and Wu B: MicroRNAs in renal cell cancer: A systematic review of clinical implications (Review). Oncol Rep 33: 1571-1578, 2015.

17. Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, et al: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 8: e53906, 2013.

18. Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW and Jeon YK: MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/Akt pathway in diffuse large B-cell lymphoma. Oncotarget 6: 15035-15049, 2015.

19. Li Y, VandenBoom TG II, Kong D, Wang Z, Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712, 2009.

20. Peng Y, Liu YM, Li LC, Wang LL and Wu XL: microRNA-503 inhibits gastric cancer cell growth and epithelial-to-mesenchymal transition. Oncol Lett 7: 1233-1238, 2014.

21. Nofech-Mozes R, Khella HW, Scorilas A, Youssef L, Krylov SN, Mirham L, Križova A, Finelli A, et al: miR-10b is a prognostic marker in clear cell renal cell carcinoma. J Clin Pathol 70: 854-859, 2017.

22. Li Y, VandenBoom TG II, Kong D, Wang Z, Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712, 2009.

23. Lee TS, Jeon HW, Kim YB, Kim YA, Kim MA and Kang SB: aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues. PLoS One 8: e81421, 2013.

24. Skaletsy R and Cullen BR: Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One 6: e24248, 2011.

25. Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. J Biol Chem 290: 8938-8948, 2015.

26. Chen X, Zhang Y, Shi Y, Lian H, Tu H, Han S, Peng B, Liu W and He X: miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bel-2. Int J Oncol 47: 1603-1611, 2015.

27. Wu DD, Li XS, Meng XN, Yan J and Zong ZH: MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1. Tumour Biol 37: 10499-10506, 2016.

28. Cui J, Bi M, Overstreet AM, Yang Y, Li H, Leng Y, Qian K, Huang Q, Zhang C, Lu Z, et al: miR-873 regulates Erb transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene 22: 1-13, 2014.

29. Gao Y, Xue Q, Wang D, Du M, Zhang Y and Gao S: miR-873 induces lung adenocarcinoma cell proliferation and migration by targeting SRCR1. Am J Transl Res 7: 2519-2526, 2015.

30. Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY, Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, et al: MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. J Pathol 232: 415-427, 2014.

31. Miao Y, Li J, Qiu X, Li Y, Wang Z and Luan Y: miR-27a regulates the self renewal of the H446 small cell lung cancer cell line in vitro. Oncol Rep 29: 161-168, 2013.

32. Li XX, Huang LY, Peng JJ, Lian SH, Shi ZH, Zheng HT and Cai SJ: Klotho suppresses growth and invasion of colon cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway. Int J Oncol 45: 611-618, 2014.

33. Qu L, Deng B, Zeng Y and Cao Z: Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer. Cancer Cell Int 14: 28, 2014.

34. Michael MZ, O'Conner SM, van Holst Pellekaan NG, Young GP and James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891, 2003.

35. Orang AV and Barzegari A: MicroRNAs in colorectal cancer: From diagnosis to targeted therapy. Asian Pac J Cancer Prev 15: 6989-6999, 2014.

36. Kijima T, Hazama S, Tsunedomi R, Tanaka H, Takenouchi H, Kanekiyto S, Inoue Y, Nakashima M, Iida M, Sakamoto K, et al: MicroRNA-6826 and -6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. Oncol Rep 37: 23-30, 2017.

37. Wang J, Du Y, Liu X, Cho WC and Yang Y: MicroRNAs as regulator of signaling networks in metastatic colon cancer. Biomed Res Int 2015: 523620, 2015.

38. Amirkhah R, Schmitz U, Linnebacher M, Wolkenhauer O and Farazmand A: MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression. Genes Chromosomes Cancer 54: 129-141, 2015.

39. Ren L, Xiao L, Hu J, Li Z and Wang Z: MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci 27: 721-724, 2007.

40. Moldawer LL, Copeland EM III and Mackay S: Nuclear factor-κB and Inflammation in sepsis and septic shock. Crit Care Med 35: 318-328, 2007.

41. Hayden MS and Ghosh S: Signaling to NF-kappaB. Genes Dev 18: 660-670, 2004.

42. Sen R and Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46: 705-716, 1986.

43. Sakamoto K and Maeda S: Targeting NF-κB for colorectal cancer therapy. Pharmacol Rev 58: 518-523, 2006.

44. Sen R and Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46: 705-716, 1986.

45. Voboril R and Weberova-Voborilova J: Constitutive NF-κB activity in colorectal cancer: Impact on radiation-induced NF-κB activation, radiosensitivity, and apoptosis. Neoplasma 53: 518-523, 2006.

46. Lind DS, Hochwald SN, Malaty J, Rekiks S, Hebig P, Mishra G, Moldawer LL, Copeland EM III and Mackay S: Nuclear factor-xκB is upregulated in colorectal cancer. Surgery 130: 363-369, 2001.

47. Wang S, Liu Z, Wang L and Zhang X: NF-kappaB signaling pathway: inflammation and colorectal cancer. Cell Mol Immunol 6: 327-334, 2009.

48. Vaiopoulos AG, Athanasoula KC and Papavassiliou AG: NF-kappaB in colorectal cancer. J Mol Med (Berl) 91: 1029-1037, 2013.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.